• 1
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
  • 2
    Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47: 1-39.
  • 3
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
  • 4
    Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278.
  • 5
    Murphy EL, Bryzman S, Williams AE, Co-Chien H, Schreiber GB, Ownby HE, et al. Demographic determinants of hepatitis C virus seroprevalence among blood donors. JAMA 1996; 275: 995-1000.
  • 6
    Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). HEPATOLOGY 2000; 31: 756-762.
  • 7
    Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-270.
  • 8
    Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. HEPATOLOGY 2012; 55: 1652-1661.
  • 9
    Robinson GM, Reynolds JN, Robinson BJ. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users. N Z Med J 1995; 108: 103-105.
  • 10
    Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645-653.
  • 11
    Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 2012; 107: 1057-1065.
  • 12
    Centers for Disease Control and Prevention. Viral Hepatitis Surveillance—United States, 2009. Accessed on 8/6/12.
  • 13
    Thomas DL. Advances in the treatment of hepatitis C virus infection. Top Antivir Med 2012; 20: 5-10.
  • 14
    Schooley RT. Hepatitis C virus therapeutics: at the end of the beginning. Top Antivir Med 2012; 20: 17-19.
  • 15
    Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366: 273-275.
  • 16
    Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA 2012; 307: 1259-1260.
  • 17
    Sroczynski G, Esteban E, Conrads Frank A, Schwarzer R, Mühlberger N, Wright D, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009; 19: 245-253.
  • 18
    Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140: 465-479.
  • 19
    Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001; 111: 614-621.
  • 20
    Ward JW, Valdiserri RO, Koh HK. Hepatitis C virus prevention, care, and treatment: from policy to practice. Clin Infect Dis 2012; 55( Suppl. 1): S58-S63.
  • 21
    Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin Infect Dis 2012; 54: 1167-1178.
  • 22
    Braverman S. One in five U.S. adults with one or more tattoos. In: Harris Interactive. New York, NY: Harris Interactive; 2012.
  • 23
    Laumann AE, Derick AJ. Tattoos and body piercings in the United States: a national data set. J Am Acad Dermatol 2006; 55: 413-421.
  • 24
    Mayers LB, Chiffriller SH. Body art (body piercing and tattooing) among undergraduate university students: “then and now”. J Adolesc Health 2008; 42: 201-203.
  • 25
    Carroll ST, Riffenburgh RH, Roberts TA, Myhre EB. Tattoos and body piercings as indicators of adolescent risk-taking behaviors. Pediatrics 2002; 109: 1021-1027.
  • 26
    Benjamins LJ, Risser WL, Cromwell PF, Feldmann J, Bortot AT, Eissa MA, et al. Body art among minority high school athletes: prevalence, interest and satisfaction; parental knowledge and consent. J Adolesc Health 2006; 39: 933-935.
  • 27
    Armstrong ML, Murphy KP, Sallee A, Watson MG. Tattooed army soldiers: examining the incidence, behavior, and risk. Mil Med 2000; 165: 135-141.
  • 28
    Zuniga IA, Chen JJ, Lane DS, Allmer J, Jimenez-Lucho VE. Analysis of a hepatitis C screening programme for US veterans. Epidemiol Infect 2006; 134: 249-257.
  • 29
    Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder JL, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. HEPATOLOGY 2005; 41: 88-96.
  • 30
    Briggs ME, Baker C, Hall R, Gaziano JM, Gagnon D, Bzowej N, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. HEPATOLOGY 2001; 34: 1200-1205.
  • 31
    Post JJ, Dolan KA, Whybin LR, Carter IW, Haber PS, Lloyd AR. Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Med J Aust 2001; 174: 183-184.
  • 32
    Thompson SC, Hernberger F, Wale E, Crofts N. Hepatitis C transmission through tattooing: a case report. Aust N Z J Public Health 1996; 20: 317-318.
  • 33
    Tsang TH, Horowitz E, Vugia DJ. Transmission of hepatitis C through tattooing in a United States prison. Am J Gastroenterol 2001; 96: 1304-1305.
    Direct Link:
  • 34
    Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-1696.
  • 35
    Hellard ME, Aitken CK, Hocking JS. Tattooing in prisons—not such a pretty picture. Am J Infect Control 2007; 35: 477-480.
  • 36
    Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J Infect 2009; 58: 375-382.
  • 37
    Gyarmathy VA, Neaigus A, Miller M, Friedman SR, Des Jarlais DC. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. J Acquir Immune Defic Syndr 2002; 30: 448-456.
  • 38
    Roy E, Haley N, Leclerc P, Boivin JF, Cedras L, Vincelette J. Risk factors for hepatitis C virus infection among street youths. CMAJ 2001; 165: 557-560.
  • 39
    Flamm SL, Parker RA, Chopra S. Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentified source of transmission. Am J Gastroenterol 1998; 93: 597-600.
    Direct Link:
  • 40
    Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253-263.
  • 41
    Alter MJ, Gerety RJ, Smallwood LA, Sampliner RE, Tabor E, Deinhardt F, et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982; 145: 886-893.
  • 42
    Wejstal R. Sexual transmission of hepatitis C virus. J Hepatol 1999; 31( Suppl. 1): 92-95.
  • 43
    Doerrbecker J, Friesland M, Ciesek S, Erichsen TJ, Mateu-Gelabert P, Steinmann J, et al. Inactivation and survival of hepatitis C virus on inanimate surfaces. J Infect Dis 2011; 204: 1830-1838.
  • 44
    Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol 2007; 28: 519-524.
  • 45
    Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis 2010; 202: 984-990.
  • 46
    Steinmann E, Ciesek S, Friesland M, Erichsen T, Pietschmann T. Prolonged survival of hepatitis C virus in the anesthetic propofol. Clin Infect Dis 2011; 53: 963-964.
  • 47
    Strang J, Heuston J, Whiteley C, Bacchus L, Maden T, Gossop M, et al. Is prison tattooing a risk behaviour for HIV and other viruses? Results from a national survey of prisoners in England and Wales. Crim Behav Ment Health 2000; 10: 60-65.